niftify.in

Business Standard

Piramal Pharma receives SBTi validation for its GHG commitment

Piramal Pharma has embarked on its sustainability journey as the Science Based Targets initiative (SBTi) officially validated the company's near-term greenhouse gas (GHG) emission reduction targets. This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,' driving its business strategies and strengthening the company's commitment to making consistent, measurable progress toward a more sustainable future.

Mint

Piramal Pharma share price jumps 23% in September so far and 68% YTD; investors could 'buy on dips' says analyst

Piramal Pharma share price surged 23% in September and 68% YTD, driven by strong trading volumes and growth prospects. A minor correction occurred due to profit booking. The US Biosecure Act boosts confidence in Indian CDMO players, potentially increasing business opportunities.

CNBC TV18

US House passes Biosecure Act - How will it impact Indian Pharma

Shares of Laurus, Syngene and Piramal Pharma are trading at or near to their 52-week high levels.

The Economic Times

Technical Breakout Stocks: How to trade Glenmark Pharma, Piramal Pharma and Suven Life on Monday

The Indian market closed in the red for the fourth consecutive day, with the Sensex falling over 1,000 points and Nifty50 below 24,900. Despite this, Glenmark Pharma, Piramal Pharma, and Suven Pharma showed positive trends. Analysts suggest a bullish outlook for these stocks based on recent technical indicators.

CNBC TV18

Analysts see upside in Piramal Pharma, JSW Holdings, Pidilite Industries, GNFC and Dabur India

On Thursday, market tech analysts Apurva Sheth and Mitessh Thakkar recommended these stocks for the short term.

Business Standard

Piramal Pharma hits record high in weak market; surges 12% on heavy volumes

As many as 43.42 million equity shares, representing 3.3 per cent of total equity of the pharma company, had changed hands on the NSE till afternoon

Business Line

Stock to buy today: Piramal Pharma (₹166.35)

Place stop-loss at ₹145